Vaccines and drugs have helped reduce disease severity and blunt the spread of severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, ongoing virus …

Protease inhibitors are among the most powerful antiviral drugs. Nirmatrelvir is the first
protease inhibitor specifically developed against the SARS-CoV-2 protease 3CLpro that has …

The COVID‐19 pandemic remains a major health concern worldwide, and SARS‐CoV‐2 is
continuously evolving. There is an urgent need to identify new antiviral drugs and develop …

Proteases encoded by SARS-CoV-2 constitute a promising target for new therapies against
COVID-19. SARS-CoV-2 main protease (Mpro, 3CLpro) and papain-like protease (PLpro) …

COVID‑19 has swept through mainland China by human‑to‑human transmission. The rapid
spread of SARS‑CoV‑2 and its variants, including the currently prevalent Omicron strain …

Human coronaviruses (hCoVs) infect millions of people every year. Among these, MERS,
SARS-CoV-1, and SARS-CoV-2 caused significant morbidity and mortality and their …

Although global vaccination campaigns alleviated the SARS-CoV-2 pandemic in terms of
morbidity and mortality, the ability of the virus to originate mutants may reduce the efficacy of …

Abstract The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is an epidemic,
zoonotically emerging pathogen initially reported in Saudi Arabia in 2012. MERS-CoV has …

Abstract Nonstructural protein 5 (Nsp5) is the main protease of SARS-CoV-2 that cleaves
viral polyproteins into individual polypeptides necessary for viral replication. Here, we show …

Nirmatrelvir was the first protease inhibitor specifically developed against the SARS-CoV-2
main protease (3CLpro/Mpro) and licensed for clinical use. As SARS-CoV-2 continues to …